Armata Pharmaceuticals (ARMP) said Monday its Good Manufacturing Practice manufacturing facility in Los Angeles, California, has been commissioned.
The company said it has notified the US Food and Drug Administration that production has started, and production runs have been completed with no issues.
The plant allows Armata to make its multi-phage cocktails to support clinical trials, the company said.
Price: 5.92, Change: +0.14, Percent Change: +2.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.